ZLAB Zai Lab Ltd Insider Trading

CEO/then-Chair Du Ying sold 100,000 ZLAB shares for $1,986,875 via scheduled 10b5-1 plan; stock down 58.6% YTD, company unprofitable with $-51.0M net loss

Du Ying, who was Chairperson & CEO at the time of filing, executed 2 separate sales totaling 100,000 shares for $1,986,875.00 on May 15 and May 18, 2026 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, reducing holdings by 8.2% to 1,122,626 shares. The sales occurred as ZLAB's stock trades at $18.37, down 58.6% from its 52-week high of $44.34, with 30-day and 90-day declines of 24.1% and 9.0% respectively, while the company reported negative net income of $-51,016,000.00 against quarterly revenue of $99,611,000.00. His prior 5 sales at ZLAB (March 2026) all showed positive 30-day and 90-day returns, contrasting with the steep post-transaction decline now underway. The scheduled-plan nature of this filing precludes timing characterization, but the backdrop of significant stock deterioration and persistent unprofitability warrants investor attention to the company's fundamental trajectory and capital allocation.

ZLAB CEO Du Ying sells 100,000 shares for $2.0M via scheduled 10b5-1 plan; stock down -11.4% in 30 days, -53.6% from 52-week high.

Du Ying executed 5 separate sales totaling 100,000 shares for $2,003,044.43 on 2026-05-13 and 2026-05-14 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, reducing her holdings from 1.22M shares to 1.12M shares. The transaction is scheduled and non-discretionary; pricing varied significantly across tranches (from $1.74 to $20.22 per share), reflecting market conditions during the execution window. The company is unprofitable (net income $-51,016,000.00), though revenue stands at $99,611,000.00 with annual growth of +15.3%. At current price of $20.59, the stock trades -53.6% from its 52-week high of $44.34 and is down -11.4% over the prior 30 days, a sharp decline from where some of these shares were sold.